Capping agent for nucleic acid pharmaceutical synthesis
Patented capping agent
In the process of capping for nucleic acid synthesis, it has been reported that the presence of 1,3,5-trimethylhexahydro-1,3,5-triazine in the capping agent leads to the formation of undesirable adducts. Honeywell's patent describes an invention of a nucleic acid synthesis method using a capping agent that essentially does not contain 1,3,5-trimethylhexahydro-1,3,5-triazine, proposing ultra-high purity capping agents.
- Company：林純薬工業 試薬化成品部
- Price：Other
